Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 12, 2013, Pages

  Ke, Wei Ming ^a   Chen, L S ^b   Parng, I M ^b   Chen, W W ^a   On, A W F ^a  

^a Taiwan Drug Relief Foundation   (Taiwan)

^b Office for HealthCare Quality Measurement   (Taiwan)

Author keywords

Claims database; Pharmacovigilance; TB screening

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING TEST; TAIWAN; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888110414     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0368     Document Type: Article

References (26)

1. Lawn S D, Zumla A I. Tuberculosis. Lancet 2011; 378: 57-72.
2. Lo H Y, Chou P, Yang S L, et al. Trends in tuberculosis in Taiwan, 2002-2008. J Formos Med Assoc 2011; 110: 501-510.
3. Kuo H-S, ed. Taiwan tuberculosis control report 2009. Taipei, Taiwan: Taiwan Center for Disease Control, 2009.
4. Lin J, Ziring D, Desai S, et al. TNF-alpha blockade in human diseases: an overview of efficacy and safety. Clinical Immunol 2008; 126: 13-30. (Pubitemid 350266448)
5. Keane J, Gershon S, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
6. Bongartz T, Sutton A J, Sweeting M J, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285. (Pubitemid 43736578)
7. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412. (Pubitemid 41612206)
8. Burmester G R, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-739. (Pubitemid 46846691)
9. Askling J, Fored C M, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992. (Pubitemid 40994319)
10. Dixon W G, Hyrich K L, Watson K D, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.
11. Favalli E G, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.Autoimmun Rev 2009; 8: 266-273.
12. Gomez-Reino J J, Carmona L, Descalzo M A. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761. (Pubitemid 46932080)
13. Gomez-Reino J J, Carmona L, Valverde V R, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
14. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
15. Nam J L, Winthrop K L, van Vollenhoven R F, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-986.
16. Singh J A, Wells G A, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview.Cochrane Database Syst Rev 2011(2): CD008794.
17. Schiff M H, Burmester G R, Kent J D, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.Ann Rheum Dis 2006; 65: 889-894.
18. Seong S S, Choi C B, Woo J H, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-711.
19. Taiwan Ministry of Health and Welfare. National health insurance profile (updated 2009.06.05). Taipei, Taiwan: NHI, http://www.nhi.gov.tw/Resource/ webdata/13767-1-NHI-2012-2013%20ANNUAL%20REPORT.pdf Accessed October 2013.
20. Saag K G, Teng G G, Patkar N M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784. (Pubitemid 351847559)
21. Lo H Y, Yang S L, Chou P, et al. Completeness and timeliness of tuberculosis notification in Taiwan. BMC Public Health 2011; 11: 915.
22. Bowerman R J. Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan. Int J Tuberc Lung Dis 2004; 8: 1228-1233. (Pubitemid 39371836)
23. Chan P-C, Chang L-Y, Wu Y-C, et al. Age-specific cut-offs for the tuberculin skin test to detect latent tuberculosis in BCG-vaccinated children. Int J Tuberc Lung Dis 2008; 12: 1401-1406.
24. Lee S S, Chou K J, Su I J, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISpot, and tuberculin skin test. Infection 2009; 37: 96-102.
25. Yeh Y P, Luh D L, Chang S H, et al. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. Trans R Soc Trop Med Hyg 2005; 99: 509-516. (Pubitemid 40692064)
26. Luh K-T, ed. Taiwan guidelines for TB diagnosis and treatment. 4th ed. Taipei, Taiwan: Taiwan Center for Disease Control, 2011.